ArticleInfection and immunity2015
CX3CR1 is dispensable for control of mucosal Candida albicans infections in mice and humans.
Article in Infection and immunity, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 34 citations in OpenAlex.
- Pathophysiological Roles of the CX3CL1-CX3CR1 Axis in Renal Disease, Cardiovascular Disease, and Cancer.International journal of molecular sciences · 2025Review
- Strain background interacts with chromosome 7 aneuploidy to determine commensal and virulence phenotypes in Candida albicans.PLoS genetics · 2025Article
- Protection against lethal sepsis following immunization withInfection and immunity · 2023Article
- Exploiting antifungal immunity in the clinical context.Seminars in immunology · 2023Review
- A New Phenotype inmBio · 2023Article
- Pathogenesis and virulence ofVirulence · 2022Review
- Regulation and function of CX3CR1 and its ligand CX3CL1 in kidney disease.Cell and tissue research · 2021Review
- Challenges and Opportunities in Understanding Genetics of Fungal Diseases: Towards a Functional Genomics Approach.Infection and immunity · 2021Review
- Aberrant type 1 immunity drives susceptibility to mucosal fungal infections.Science (New York, N.Y.) · 2021Article
- Polymorphisms within theInfection and immunity · 2020Article
- Advances in Understanding Human Genetic Variations That Influence Innate Immunity to Fungi.Frontiers in cellular and infection microbiology · 2020Review
- Improved in vitro and in vivo Anti-International journal of nanomedicine · 2020Article
- Genetic variation and fungal infection risk: State of the art.Current fungal infection reports · 2019Article
- EphA2 Is a Neutrophil Receptor for Candida albicans that Stimulates Antifungal Activity during Oropharyngeal Infection.Cell reports · 2019Article
- Genome Sequence for Candida albicans Clinical Oral Isolate 529L.Microbiology resource announcements · 2019Article
- Article
- Candida albicans induces mucosal bacterial dysbiosis that promotes invasive infection.PLoS pathogens · 2019Article
- VT-1598 inhibits the in vitro growth of mucosal Candida strains and protects against fluconazole-susceptible and -resistant oral candidiasis in IL-17 signalling-deficient mice.The Journal of antimicrobial chemotherapy · 2018Article
- CX3CR1Science (New York, N.Y.) · 2018Article
- VT-1161 protects mice against oropharyngeal candidiasis caused by fluconazole-susceptible and -resistant Candida albicans.The Journal of antimicrobial chemotherapy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 7 institutions in 2 countries.
Funding
Abstract
Candida albicans is part of the normal commensal microbiota of mucosal surfaces in a large percentage of the human population. However, perturbations of the host's immune response or bacterial microbiota have been shown to predispose individuals to the development of opportunistic Candida infections. It was recently discovered that a defect in the chemokine receptor CX3CR1 increases susceptibility of mice and humans to systemic candidiasis. However, whether CX3CR1 confers protection against mucosal C. albicans infection has not been investigated. Using two different mouse models, we found that Cx3cr1 is dispensable for the induction of interleukin 17A (IL-17A), IL-22, and IL-23 in the tongue after infection, as well as for the clearance of mucosal candidiasis from the tongue or lower gastrointestinal (GI) tract colonization. Furthermore, the dysfunctional human CX3CR1 allele CX3CR1-M280 was not associated with development of recurrent vulvovaginal candidiasis (RVVC) in women. Taken together, these data indicate that CX3CR1 is not essential for protection of the host against mucosal candidiasis, underscoring the dependence on different mammalian immune factors for control of mucosal versus systemic Candida infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.